Company intelligence / Profile preview
Teikoku Pharma
San Jose, California, United Statesteikokuusa.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Teikoku Pharma USA has successfully commercialized Lidoderm (Lidocaine 5% Patch) and is developing TPU-006, a 4-day dexmedetomidine patch for post-operative pain management which has received FDA Fast Track Designation. Their parent company recently launched ALLYDONE patches in Japan for Alzheimer's disease treatment.
- Therapeutic areas
- Neurology
- Modalities
- Transdermal patchestopical formulationsoral formulations
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Teikoku Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Teikoku Pharma.